- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Complaint alleged pre-licence promotion via a LinkedIn post linking to a GSK press release about Aiolos Bio acquisition and AIO-001 in asthma.…
GSK-sponsored COPD decision support tool lacked a prominent sponsorship declaration at the outset of the homepage after sponsorship ended. PMCPA ruled a…
Two Alliance representatives raised litigation/medico-legal consequences during a promotional meeting about Eliquis amid cost-driven switching to Lixiana. The Panel found scaremongering and…
A pharmacist challenged a Lyrinel XL ad’s “Gets our vote” imagery. The Panel found the illustration exaggerated satisfaction by ignoring discontinuations and…
Teva challenged two Trinity-Chiesi clinical support service pharmacist forms implying increased use of Clenil Modulite. The Panel found the complaint was too…
AstraZeneca challenged Trinity-Chiesi’s Fostair cost comparison chart as incomplete and misleading versus Symbicort and Seretide. The Panel found the chart acceptable in…
Complaint about Lantus promotional leavepieces and a mailer. Issues included “24-hour efficacy” wording and a hypoglycaemia comparison based on pooled observational data.…
A GP complained about an unsolicited promotional email for MacroBid sent to his NHS email via an agency. The Panel and Appeal…
AstraZeneca self-reported an uncertified promotional email about Crestor sent to a dispensing practice. The email and attached slides lacked prescribing information and…
An oncologist complained about “magnetic words” enclosed with an Arimidex mailing. The Panel said it was a promotional aid, not relevant to…
A Lipitor mailer compared LDL-C lowering across statins but then implied only Lipitor/rosuvastatin/ezetimibe combos had outcomes evidence. Panel found this misleading and…
Bayer Schering was found to have promoted Xarelto (rivaroxaban) before UK authorisation via a UK congress exhibition panel and a JBJS “supplement”…
ProStrakan’s withdrawn Abstral ad reappeared in the BMJ after prior undertakings. Panel found breaches of Clauses 25 and 9.1 due to inadequate…
Duac materials implied use beyond mild–moderate acne, claimed it “starts working within a week” without evidence <7 days, and a sponsored GP…
Complaint alleged cumulative recent Gaviscon Advance breaches brought the industry into disrepute (Clause 2). Panel noted prior breaches but ruled no breach…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.